Clinical features and management of BRCA1 and BRCA2-associated prostate cancer.

@article{Alanee2014ClinicalFA,
  title={Clinical features and management of BRCA1 and BRCA2-associated prostate cancer.},
  author={Shaheen Alanee and Emily A Glogowski and Kasmintan A. Schrader and James Eastham and Kenneth Offit},
  journal={Frontiers in bioscience},
  year={2014},
  volume={6},
  pages={
          15-30
        }
}
It is thought that over forty percent of an individual's risk of developing prostate cancer (PCa) is related to familial and genetic factors. Although multiple genes have been implicated in the development of PCa, few confer as high a risk as mutations in the genes associated with early-onset breast cancer (BRCA1 and BRCA2). Not only do mutations in BRCA genes increase the risk of PCa, but they have also been related to adverse disease characteristics and outcomes. Therefore, a better… 

Figures from this paper

Clinical Management of Prostate Cancer in Men with BRCA Mutations.
BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management.
TLDR
The authors review the etiopathogenesis and imaging features of BRCA-associated malignancies, the importance of a multidisciplinary approach to determining the diagnosis, and the treatment of patients who have these mutations to improve their outcomes.
Management of Male BRCA Mutation Carriers
TLDR
The management of male breast cancer has been extrapolated from the available evidence derived in studies of female breast cancer, in particular, postmenopausal, estrogen receptor-positive (ER+) tumors.
The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers
TLDR
The review concludes that as more knowledge arises about the mechanisms of BRCA1/2 gene mutations, it should pave the way for future screening programmes to be applied effectively.
Hematologic Presentation of Metastatic Prostate Carcinoma: A Case Report on a Brca2 Mutated Young Patient
TLDR
The diagnosis of a BRCA2 mutation may be helpful in terms of genetic counseling, risk assessement and early screening for patients with prostate cancer who have germline/somatic modifications in the DNA restoration pathway mechanism for BRC a1 and BRCa2.
Survival outcomes in men with a positive family history of prostate cancer: a registry based study
TLDR
Men with a positive family history of PCa appear to have better overall survival outcomes, and this better survival may represent lead time bias and early initiation of PSA screening.
Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer – a SEER analysis
TLDR
The incidence of prostate cancer in men with history of breast cancer is similar to the general population, and men with favorable characteristics of their breast cancer were more likely to develop prostate cancer, possibly due to a lower competing risk of Breast cancer mortality.
Analysis of resistance-associated gene expression in docetaxel-resistant prostate cancer cells.
TLDR
The results suggest that BRCA2 serves an important role in the docetaxel resistance of prostate cancer cells and BRC a2 modulation may be a strategy to partially reverse docetAXel resistance in prostate cancer.
Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers
TLDR
Analysis of all reported germline BRCA2mut prostate cancer cases allows better understanding of the clinicopathologic features and survival outcomes of these men.
...
...

References

SHOWING 1-10 OF 153 REFERENCES
Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations
TLDR
The results indicate that the BRCA2 founder mutation confers a 3-fold elevated risk of high-grade prostate cancer and should be carefully considered in genetic counseling and/or evaluating therapeutic options.
Decreased Prostate Cancer-Specific Survival of Men with BRCA2 Mutations from Multiple Breast Cancer Families
TLDR
There was a poor overall survival outcome for both the BRCA2 mutation carriers and noncarriers given curative-intent treatment, which is significant and should be included in discussions with genetic counselors and medical professionals when discussing prostate cancer treatment options for men in these families, irrespective of mutation status.
Correlation of germ-line BRCA2 mutations with aggressive prostate cancer and outcome.
  • E. Castro, C. Goh, R. Eeles
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
The results confirm that PCa pts with BRCA mutations have a poor outcome and both BRC a1 and BRCa2mutation carriers with PCa are more likely to have nodal involvement and metastasis at diagnosis and earlier disease progression.
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene.
TLDR
It is confirmed that BRCA2 is a high-risk prostate-cancer-susceptibility gene and have potential implications for the management of early-onset prostate cancer, in both patients and their relatives.
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
TLDR
Among women with high-grade serous ovarian cancer, BRCA2 mutation, but not BRC a1 deficiency, was associated with improved survival, improved chemotherapy response, and genome instability compared with BRCa wild-type.
An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.
TLDR
BRCA mutation-associated PAC represents an underidentified, but clinically important, subgroup of patients that may potentially offer a significant benefit to a genetically selected population given the ongoing development of therapeutic agents targeting DNA repair.
Germline Mutations in the BRCA2 Gene and Susceptibility to Hereditary Prostate Cancer
TLDR
No evidence was found in this study for an association between BRCA2 mutations and susceptibility to HPC in men selected from high-risk families.
BRCA1 and BRCA2 have a limited role in familial prostate cancer.
TLDR
BRCA1 and BRCA2 appear to have a limited role in familial prostate cancer, and families with both prostate and breast cancer may result from mutations in other predisposition genes.
Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer
TLDR
It is estimated that <1% of early-onset prostate cancers in the general US Caucasian population can be attributed to these rare disease-associated BRCA2 mutations, and results suggest that protein-truncating BRCa2 mutations confer an elevated RR ofEarly-onsets prostate cancer.
Germline BRCA1 mutations increase prostate cancer risk
TLDR
This study shows evidence for an increased risk of PrCa in men who harbour germline mutations in BRCA1, which could have a significant impact on possible screening strategies and targeted treatments.
...
...